IN NAD for Management of Tremors and Symptoms Associated with Parkinson’s Disease

Descriptive Investigation of Intranasal Administration of Nicotinamide Adenine Dinucleotide for Management of Tremors and Symptoms Associated with Parkinson’s Disease

*Z. KING 1, S. L. BROOM 1,3, T. OLDS 2,3, R. F. MESTAYER 3.

1 Dept. of Psychol., William Carey Univ., Hattiesburg, MS;

Springfield Wellness Center, Springfield, LA;

3 NAD Research, Inc., Springfield, LA

Introduction

Parkinson’s disease (PD) is a neurodegenerative disease that causes individuals to experience cognitive impairment and motor dysregulation. Previous research documents a relationship between the neurodegeneration found in PD and the normal depletion of Nicotinamide Adenine Dinucleotide (NAD+) – a coenzyme found in all living cells which depletes with age. Clinicians at Springfield Wellness Center have developed intravenous NAD+ administration protocols for treatment of a number of clinical conditions: detox mood and anxiety disorders, and symptoms associated with Alzheimer’s and Parkinson’s Disease. Collaborative efforts with physicians specializing in the use of NAD+ sphenocath/sphenopalatine ganglion block protocols resulted in effective treatment and management of migraine headache pain, suggesting that (IN) NAD+ is an effective strategy for management of symptoms associated with these conditions. We present data from three patients with Parkinson’s disease who have undergone an initial 6-day (IV) NAD treatment administration protocol followed by administration of (IN) NAD+ treatment for PD symptom management over a 2 year follow up period.

Method

Acknowledgments/References
Three patients (#1,2,3) sought treatment at Springfield Wellness Center between Jan 2020-Nov 2022 for symptoms associated with PD; Pts 1 and 3 reported symptom onset 2 years prior, while Pt 2 reported onset 3m prior. Following the initial 6-day (IV) NAD+ treatment (1000 mg of NAD+ per day), patients were given the option to enroll in a maintenance program using (IN) NAD+ (200 mg/ml NAD in either 0.5% or 2% lidocaine). Patient data during the (IN) NAD+ administration follow-up period (1-2yr) were analyzed and evaluated using clinic-derived consultation and procedural questionnaires that measured symptoms of pain, stress, energy, and sleep, and documented daily activities to reduce stress as well as self-reported overall symptom improvement and/or changes. Tremors and other symptoms were also recorded in daily nurse notes and analyzed following treatment of (IV) NAD+.

Results

● The patients showed varying degrees of overall symptom improvement, ranging from 15% to 75% improvement over time.
● Nurse reports suggested a 50% reduction in tremors in Patient 1 and Patient 3 within the first three days of the (IV) NAD+ treatment protocol.
● Patient data indicated that intranasal administration of NAD+ following the initial (IV) NAD+ treatment protocol aided in overall symptom management.
● Patient data indicated that exercise and meditation were the primary QOL activities to reduce stress.

Conclusions

These findings indicate that the use of NAD+ administration protocols for initial treatment and follow-up show therapeutic potential in alleviating tremors and improve symptoms of pain and cognitive impairments associated with PD. The use of NAD+ in the treatment of PD could be considered a supportive add-on to traditional medications and forms of standard care; however, further studies are needed to determine the effectiveness of NAD+ in this patient population.

Acknowledgments/References

Thank you to Springfield Wellness Center for providing data for this project.
Thank you to William Carey University Quality Enhancement Plan and NAD, Research, Inc. for support on this project.

Rutherford, L., Gadol, E., Broom, S. L., Olds, T., Mestayer, R. F., et al. (2020). J Gerontol Geriatr Med, 6(46). 1-5.

Thompson, A. DiBlasio, P., Dyess, G.A., Broom, S.L., Mestayer, R.F. (Mar 2022). Mississippi Academy of Sciences, Biloxi, MS.

White, J., Podesta, A., Dyess, G.A., Broom, S.L., Mestayer, R.F. (Nov 2022).